DoD awards $1.77B for COVID-19 antigen tests, with IHealth Labs Inc. as primary contractor

Contract Overview

Contract Amount: $1,774,999,987 ($1.8B)

Contractor: Ihealth Labs Inc.

Awarding Agency: Department of Defense

Start Date: 2022-01-12

End Date: 2022-07-05

Contract Duration: 174 days

Daily Burn Rate: $10.2M/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Number of Offers Received: 20

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: COVID-19 ANTIGEN TEST

Place of Performance

Location: SUNNYVALE, SANTA CLARA County, CALIFORNIA, 94086

State: California Government Spending

Plain-Language Summary

Department of Defense obligated $1.77 billion to IHEALTH LABS INC. for work described as: COVID-19 ANTIGEN TEST Key points: 1. Contract value represents a significant investment in pandemic preparedness and response. 2. The award was made under full and open competition, suggesting a competitive bidding process. 3. A high number of offers (20) indicates strong market interest and potential for price discovery. 4. The contract duration of 174 days suggests a focused effort on immediate supply needs. 5. The fixed-price nature of the contract shifts performance risk to the contractor. 6. This award is a key component of the federal government's strategy to ensure widespread access to testing.

Value Assessment

Rating: good

The contract value of $1.77 billion for COVID-19 antigen tests is substantial, reflecting the scale of national testing needs. Benchmarking against other large-scale procurements for similar diagnostic supplies is challenging due to the unique market conditions during the pandemic. However, the number of offers received suggests that the pricing was likely competitive. The firm fixed-price structure provides cost certainty for the government, assuming the contractor can manage production and delivery within the agreed-upon terms.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under 'full and open competition after exclusion of sources,' indicating that while the competition was broad, specific circumstances led to the exclusion of certain potential bidders. The solicitation received 20 offers, demonstrating a robust level of interest from the market. A high number of bidders generally supports competitive pricing and allows the government to select the offer that best meets its requirements in terms of price, quality, and delivery.

Taxpayer Impact: The extensive competition for this contract is beneficial for taxpayers, as it likely drove down the per-unit cost of the antigen tests and ensured the government secured a reliable supply chain at a reasonable price.

Public Impact

The primary beneficiaries are the American public, who gain access to essential COVID-19 testing resources. Services delivered include the manufacturing and supply of COVID-19 antigen test kits. The geographic impact is national, supporting public health initiatives across the United States. Workforce implications include potential job creation in manufacturing and logistics sectors related to test production.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for supply chain disruptions impacting delivery timelines.
Ensuring consistent quality control across a large volume of manufactured tests.
Dependence on a single primary contractor (IHEALTH LABS INC.) for a significant portion of the supply.

Positive Signals

Large-scale procurement addresses critical public health needs during a pandemic.
Competitive bidding process likely secured favorable pricing for the government.
Contract structure provides clear performance expectations and cost controls.

Sector Analysis

The procurement of COVID-19 antigen tests falls within the broader healthcare and life sciences sector, specifically in the area of in-vitro diagnostics manufacturing. The market for diagnostic tests saw unprecedented growth and demand during the pandemic. This contract represents a significant portion of the federal government's investment in ensuring the availability of rapid testing solutions, complementing other public health strategies. Comparable spending benchmarks are difficult to establish due to the unique market dynamics and scale of pandemic-driven demand.

Small Business Impact

Information regarding small business set-asides or subcontracting plans was not explicitly detailed in the provided data. However, given the large scale of this definitive contract, it is possible that opportunities for small businesses may exist within the supply chain or through subcontracting arrangements, though this would require further investigation into the contractor's specific utilization plans.

Oversight & Accountability

Oversight for this contract would typically be managed by the contracting officer and the relevant program office within the Department of the Army. Accountability measures are embedded in the firm fixed-price contract terms, requiring the contractor to deliver specified goods by a certain date. Transparency is generally maintained through contract award databases, although specific performance metrics and ongoing oversight activities may not be publicly detailed.

Related Government Programs

COVID-19 Testing Supplies
Public Health Preparedness
Diagnostic Test Manufacturing
Department of Defense Medical Materiel

Risk Flags

Potential for supply chain vulnerabilities.
Quality control assurance for mass-produced diagnostics.
Timeliness of delivery to meet public health demands.

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $1.77 billion to IHEALTH LABS INC.. COVID-19 ANTIGEN TEST

Who is the contractor on this award?

The obligated recipient is IHEALTH LABS INC..

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $1.77 billion.

What is the period of performance?

Start: 2022-01-12. End: 2022-07-05.

What is the track record of IHEALTH LABS INC. in fulfilling large government contracts, particularly for medical supplies?

IHEALTH LABS INC. has been a significant player in the COVID-19 testing market, including substantial government contracts. Prior to and during the pandemic, the company secured agreements with various federal agencies, including the Department of Defense and the Department of Health and Human Services, for the supply of antigen tests. Their ability to scale production to meet the immense demand during the pandemic was critical. While specific details on past performance metrics for all contracts are not always publicly available, the scale of awards like this $1.77 billion contract suggests a demonstrated capacity to manage large-scale manufacturing and delivery operations. However, like any large supplier, scrutiny regarding production timelines, quality control, and adherence to delivery schedules is inherent in such high-volume contracts.

How does the per-unit cost of these antigen tests compare to other government procurements or commercial market rates during the same period?

Determining an exact per-unit cost benchmark is complex without the specific unit price from the contract award. However, the fact that this was a 'full and open competition after exclusion of sources' with 20 offers suggests a competitive environment that would likely drive unit prices down. During the height of the pandemic, prices for rapid antigen tests fluctuated significantly based on supply and demand. Government bulk purchases, especially through competitive processes, often secure more favorable pricing than individual commercial purchases. While specific comparative data is not provided, the competitive nature of this award implies that the government likely achieved a cost-effective rate relative to the market conditions and the urgency of the need.

What are the primary risks associated with this contract, and what mitigation strategies are likely in place?

Key risks for this contract include potential supply chain disruptions affecting raw materials or manufacturing capacity, quality control issues leading to a batch of substandard tests, and delivery delays impacting the availability of testing resources. Mitigation strategies likely involve robust quality assurance protocols mandated in the contract, performance clauses with penalties for non-compliance, and potentially requiring the contractor to maintain buffer stock or have contingency plans for alternative sourcing. The firm fixed-price nature also places the risk of cost overruns on the contractor. The Department of Defense's oversight would focus on ensuring timely delivery and adherence to quality specifications.

How effective has the federal government been in ensuring widespread access to COVID-19 tests through contracts like this one?

Contracts like this $1.77 billion award to IHEALTH LABS INC. have been instrumental in the federal government's strategy to ensure widespread access to COVID-19 tests. By leveraging large-scale procurements, the government aimed to distribute tests through various channels, including public health programs, pharmacies, and direct mail programs. The success of these efforts is often measured by test availability, accessibility, and utilization rates across the population. While challenges in distribution and equity have been noted throughout the pandemic, these significant contract awards represent a core component of the government's response, providing the necessary volume of tests to support public health efforts and individual testing needs.

What is the historical spending pattern for COVID-19 antigen tests by the Department of Defense, and how does this award fit within that trend?

The Department of Defense's spending on COVID-19 antigen tests has been substantial, particularly during periods of high demand and national health emergencies. This $1.77 billion award represents one of the largest single procurements for antigen tests by the DoD, reflecting a significant investment in bolstering national testing capabilities. Historically, DoD spending in this area has surged during peak pandemic waves and in response to strategic initiatives aimed at increasing testing capacity. This contract fits within a broader trend of federal agencies investing heavily in diagnostic tools to manage the pandemic, with the DoD often playing a crucial role in logistics and procurement due to its established infrastructure and contracting expertise.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: W58P0522R0003

Offers Received: 20

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 120 SAN LUCAR CT, SUNNYVALE, CA, 94086

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign-Owned and U.S.-Incorporated Business, Self-Certified Small Disadvantaged Business, Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $1,837,499,987

Exercised Options: $1,774,999,987

Current Obligation: $1,774,999,987

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline